Evidence map›Paper›PMID 28323866›Full record

ArticlePloS one2017

Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD.

Daniel Bergemalm, Robert Kruse, Maria Sapnara, Jonas Halfvarson, Elisabeth Hultgren Hörnquist

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Daniel BergemalmDepartment of Gastroenterology, Faculty of Medicine and Health, University of Örebro, Örebro, Sweden.ORCID http://orcid.org/0000-0002-1906-0746
Robert KruseSchool of Medical Sciences, Faculty of Medicine and Health, University of Örebro, Örebro, Sweden.
Maria SapnaraDepartment of Microbiology and Immunology, University of Gothenburg, Institute of Biomedicine, Gothenburg, Sweden.
Jonas HalfvarsonDepartment of Gastroenterology, Faculty of Medicine and Health, University of Örebro, Örebro, Sweden.
Elisabeth Hultgren HörnquistSchool of Medical Sciences, Faculty of Medicine and Health, University of Örebro, Örebro, Sweden.
Örebro University · SEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. On the other hand, in experimental mouse models there is probably less variation. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms.

methodsFecal samples were collected at onset of inflammation in Galphai2-/- mice, a well-described spontaneous model of chronic colitis, and from healthy littermates. The fecal proteome was analyzed by two-dimensional electrophoresis and quantitative mass spectrometry and results were then validated in a new cohort of mice.

resultsAs a potential top marker of disease, peptidase D was found at a higher ratio in Galphai2-/- mouse feces relative to controls (fold change 27; p = 0.019). Other proteins found to be enriched in Gαi2-/- mice were mainly pancreatic proteases, and proteins from plasma and blood cells. A tendency of increased calprotectin, subunit S100-A8, was also observed (fold change 21; p = 0.058). Proteases are potential activators of inflammation in the gastrointestinal tract through their interaction with the proteinase-activated receptor 2 (PAR2). Accordingly, the level of PAR2 was found to be elevated in both the colon and the pancreas of Galphai2-/- mice at different stages of disease.

conclusionsThese findings identify peptidase D, an ubiquitously expressed intracellular peptidase, as a potential novel marker of colitis. The elevated levels of fecal proteases may be involved in the pathogenesis of colitis and contribute to the clinical phenotype, possibly by activation of intestinal PAR2.

Indexed as

AnimalsBiomarkersColitisDipeptidasesDisease Models, AnimalElectrophoresis, Gel, Two-DimensionalFecesFemaleGastrointestinal TractGTP-Binding Protein alpha Subunit, Gi2InflammationMaleMass SpectrometryMiceMice, KnockoutProteomeBiomarkersDipeptidasesGnai2 protein, mouseGTP-Binding Protein alpha Subunit, Gi2proline dipeptidaseProteomeReceptors, G-Protein-Coupled

Identifiers

PMID28323866
PMCPMC5360340
OpenAlexW2602001549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.